ZNTL Presents Phase 1b MUIR Trial Data Showing 39% ORR, 7.3-Month Median PFS for Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.00
-2.9% in 3d after detection
Post-detection moves
1h
—
1d
-1.9%
3d
-2.9%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS